Results 181 to 190 of about 6,861 (225)
Some of the next articles are maybe not open access.

Population pharmacokinetics of aciclovir and its major metabolite 9-carboxymethoxymethylguanine and safety profile of valaciclovir in early liver transplant recipients.

Journal of Antimicrobial Chemotherapy
BACKGROUND Valaciclovir is frequently prescribed for cytomegalovirus infection prophylaxis. Its major metabolite 9-carboxymethoxymethylguanine (9-CMMG), when accumulated in renally impaired patients, is neurotoxic.
B. Kably   +8 more
semanticscholar   +1 more source

Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database

Expert Review of Clinical Pharmacology, 2023
Objective This study aimed to explore a comprehensive empirical investigation and assess SCARs related to valaciclovir or acyclovir based on FAERS database from FDA, thus providing a theoretical foundation for the rational application of drugs in clinic.
KaiLi Mao   +5 more
semanticscholar   +1 more source

Cytomegalovirus congenital infection: long-term outcomes in a valaciclovir treated population

Journal of Perinatal Medicine
Objectives This case series aims to evaluate the long-term outcomes of congenital cytomegalovirus (CMV) infection in a population treated with valaciclovir during pregnancy.
Maria Vicente   +4 more
semanticscholar   +1 more source

Quantification of maternal and fetal valaciclovir exposure in a pharmacokinetic study of cytomegalovirus-infected pregnant women treated to prevent vertical transmission.

Journal of Antimicrobial Chemotherapy
V. Faure-Bardon   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy